Ontology highlight
ABSTRACT:
SUBMITTER: Lin AY
PROVIDER: S-EPMC8882667 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
Lin Adam Yuh AY Schnitter Joseph Michael JM Gordon Leo I LI
ImmunoTargets and therapy 20220223
Classical Hodgkin lymphoma is biologically different than other lymphomas. The cancer cells only occupy a small amount of the lymph node and evade the immune system by amplification of PD-L1 and PD-L2. Therefore, checkpoint inhibitors are a logical treatment option for Hodgkin lymphoma patients to unlock the immune system. Checkpoint inhibitors have shown high response rates in clinical trials in advanced-stage Hodgkin lymphoma. The two most commonly used checkpoint inhibitors are pembrolizumab ...[more]